BAFFR CAR-T therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have B-cell lymphoma that came back or did not respond to treatment, including a drug targeting CD20 and an anthracycline chemo drug.
- Your cancer cells must have the BAFFR protein (confirmed by a lab test).
- You have recovered from side effects of earlier treatments (minor side effects allowed).
- You are well enough to care for yourself (ECOG score 0-2) and expected to live more than 3 months.
- Your liver, kidney, heart, and blood counts are within safe ranges (specific lab values are checked).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
This trial tests a new CAR-T cell therapy (LMY-922) that targets BAFF in people with certain blood cancers that have not responded to standard treatments. The goal is to see if it can shrink or control the cancer.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.